Oncotarget:化疗影响乳腺癌患者EVs功能

2017-07-12 Emma MedSci原创

乳腺癌(BC)是发生在乳腺腺上皮组织的恶性肿瘤,其已成为威胁女性身心健康的常见肿瘤。发表于Oncotarget的一篇文章中,研究人员探究了化疗药物对BC患者EVs及对内皮细胞(EC)功能的影响。

乳腺癌(BC)是发生在乳腺腺上皮组织的恶性肿瘤,其已成为威胁女性身心健康的常见肿瘤。细胞外囊泡(Extracellular Vesicles, EVs)是从细胞膜上脱落或者由细胞分泌的双层膜结构的囊泡状小体,其携带有细胞来源相关的多种蛋白质、脂类、DNA、mRNA、miRNA等,参与细胞间通讯、细胞迁移、血管新生和免疫调节等过程。

发表于Oncotarget的一篇文章中,研究人员探究了化疗药物对BC患者EVs及对内皮细胞(EC)功能的影响。研究人员从74位女性血液样品中分离EVs,其中有25位新辅助化疗BC患者,29位辅助化疗BC患者以及20位健康女性。采样时间在化疗前和最后一次化疗当天,部分患者在化疗24小时后也进行了样品的采集和评估。通过检测细胞来源,血栓和细胞因子含量对EVs进行表征,并同时评估EVs对内皮细胞的凝血、迁移、凋亡和增殖的影响。

研究人员进行检测和分析后发现,与健康对照组相比,两个患者组的EC-EVs明显升高,且BC标志物、MUC1和EpCAM的表达不同。与同时取样的辅助化疗患者组相比,化疗前分离的新辅助化疗患者组EVs含有更多的促血管生成蛋白,更少的内皮细胞凋亡和更多的内皮细胞迁移。在化疗结束时,EVs显示出更高的促凝血活性,并且阿霉素治疗24小时后,组织因子(TF)和TF途径抑制物(TFPI)比例显著增加。

结果显示,化疗影响BC患者EVs血栓形成和功能,而EVs可能具有作为化疗相关血栓形成的生物标志物甚至在化疗前预示血管损伤的潜力。

原始出处:

本文系梅斯医学(MedSci)原创翻译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2018-06-10 闆锋旦
  3. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-25 1301f486dcm

    化疗是双刃剑,需要临床和基础研究来评判

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-13 luominglian113

    学习了,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-13 ylzr123

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2054948, encodeId=8613205494840, content=<a href='/topic/show?id=14a9e13523' target=_blank style='color:#2F92EE;'>#EVs#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7135, encryptionId=14a9e13523, topicName=EVs)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Fri Sep 08 23:55:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795383, encodeId=428c1e9538386, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sun Jun 10 11:55:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=226138, encodeId=378c22613868, content=化疗是双刃剑,需要临床和基础研究来评判, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/777425ccaec245867e499b9754164208.jpg, createdBy=74ec2091836, createdName=1301f486dcm, createdTime=Tue Jul 25 11:34:55 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571046, encodeId=ed2e15e1046a3, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Jul 14 10:55:00 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221867, encodeId=c57122186e09, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jul 13 13:04:09 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221829, encodeId=145e2218292d, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Jul 13 11:47:25 CST 2017, time=2017-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=221817, encodeId=da1022181efa, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM7V1lG3lEERmrZh1ZAYgnIqsCAwFfLlOdXroVwBJqvTvw/0, createdBy=b2522082239, createdName=维维豆奶, createdTime=Thu Jul 13 10:55:28 CST 2017, time=2017-07-13, status=1, ipAttribution=)]
    2017-07-13 维维豆奶

    学习了

    0

相关资讯

JAMA Oncology:乳腺癌骨转移患者接受12周或4周周期唑来膦酸治疗的治疗效果比较

双膦酸盐唑来膦酸常用语骨转移患者的治疗以减少骨骼相关事件(SREs)的发生。但是对于其周期1个月的长期治疗仍存在争议。JAMA Oncology近期发表了一篇文章,研究接受标剂量的唑来膦酸或帕米膦酸二钠治疗的乳腺癌骨转移患者12周周期的唑来膦酸治疗与4周周期的唑来膦酸治疗疗效是否存在差别。

Sci Transl Med:颠覆常识!化疗反而增加了乳腺癌转移风险

在人类与癌症抗击的历程中,化疗是被我们使用了很久的一种武器。通过化学药物来抑制细胞分裂,患者的病情往往能得到立竿见影的控制。因此,在乳腺癌的治疗中,医生们往往会先对患者进行化疗,抑制患者肿瘤的生长,然后再进行手术,切除病灶。在所有人看来,这是最保险的治疗手段。

论OFS+AI更佳的用药时机

绝经前HR+高危乳腺癌患者内分泌策略之OFS联合AI的最佳用药时机:双管齐下又何妨?

CLIN CANCER RES:抗HIF-1α免疫抑制基底样乳腺癌生长且在体内具有靶向乳腺干细胞作用

三阴性乳腺癌(TNBC)是一种含有大量肿瘤干细胞的乳腺癌亚型。缺氧诱导因子-1α(HIF-1α)会诱导与干细胞有关的表达,在三阴性乳腺癌中表达上调。CIN CANCER RES近期报道了一篇文章,研究HIF-1α是否具有免疫原性以及在转基因鼠中靶向HIF-1α的疫苗是否可以影响基底样乳腺癌的生长。

SCI REP:乳腺癌妇女血清TFF1和TFF3升高!

由此可见,患有乳腺癌的妇女血清中TFF1和TFF3浓度较没有乳腺癌的妇女要高,但TFF2并不升高。

Chin Med:饮食模式的中医属性与乳腺癌发病率之间的关系

俗话说:"三分治,七分养",饮食就是其中一个内容。自古以来,我国劳动人民就十分重视饮食对人体健康的利害关系,把饮食命为人的命脉,还把饮食当作预防和治疗疾病的一个重要手段。这项回顾性横断面研究旨在探讨中国香港的妇女中乳腺癌的发病率与中医(CM)认为的饮食模式(热性、平和和寒性)之间的关联。研究共纳入了202例乳腺癌患者和202例健康妇女作为对照组,将她们根据人口统计学进行匹配。这些居住在香港法女性在